Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases—a growing healthcare challenge.
Innovation is the driving force behind our strong research and development (R&D) pipeline, with promising products in pre-clinical and clinical development. In 2010 alone, Crucell distributed more than 105 million1 vaccine doses in more than 100 countries around the world, and invested €100.0 million in R&D.
Crucell is deeply committed to being a good corporate citizen: a company that creates significant value for society. Our mission is to make a truly meaningful contribution to global health by directing our proven talent for innovation towards the fight against infectious diseases. An entrepreneurial mind-set and social responsibility go hand-in-hand at Crucell.
In 2010, over 1,700 dedicated and skilled Crucell employees worldwide worked to bring significant benefit to the lives of people worldwide. We are fully committed to the principles of corporate social responsibility (CSR) and place great value on doing more to benefit society than we strictly ‘must’ do. Our mission underlies everything we do, from our core business activities to the sharing of scientific knowledge and community outreach programs in countries where help is needed the most.
In this section you will find more information about our innovative research & development pipeline, our technologies and our marketed products.
Innovative research and development pipeline
Innovation is the driving force behind Crucell’s future growth supported by a strong R&D pipeline. Our scientists focus on the discovery and development of much-needed solutions for major threats to human health—particularly vaccines and antibodies for the prevention and treatment of infectious diseases. This has resulted in a broad pipeline of investigational products with the potential to revolutionize the fight against diseases such as influenza, rabies, malaria and tuberculosis. Read more...
Crucell’s strong research and development (R&D) pipeline is supported by a range of patented technologies. Our technologies open up new areas of research, speed our development programs
and optimize production processes. Read more...
Crucell focuses on developing and marketing vaccines and antibodies against a range of infectious diseases in the paediatric, travel and endemic, and respiratory fields. We currently have
a product portfolio of vaccines against twelve major infectious diseases, such as influenza,
hepatitis A, hepatitis B and typhoid fever. Read more...